恩格列净在脓毒症合并急性心力衰竭的2型糖尿病患者中应用1年随访疗效分析  

Efficacy of empagliflozin in type 2 diabetes mellitus patients with sepsis and acute heart failure for 1 years

作　　者：刘文婷[1] 关晓楠[1] 齐丹[1] 赵华[1] 张建军[1] LIU Wenting;GUAN Xiaonan;QI Dan;ZHAO Hua;ZHANG Jianjun(Department of Cardiology,Beijing Chao-yang Hospital,Capital Medical University,Beijing,100043,China)

机构地区：[1]首都医科大学附属北京朝阳医院心内科,北京100043

出　　处：《临床心血管病杂志》2022年第6期501-504,共4页Journal of Clinical Cardiology

摘　　要：目的:探讨恩格列净在脓毒症合并急性心力衰竭(心衰)的2型糖尿病患者中应用的疗效。方法:纳入脓毒症合并急性心力衰竭的糖尿病患者共180例,按不同治疗方式分为恩格列净组(79例)和对照组(101例),比较2组患者12个月全因死亡及心衰再入院的发生率。应用Kaplan-Meier(K-M)法绘制生存曲线,应用Cox回归分析再入院的危险因素。结果:2组患者12个月全因死亡率差异无统计学意义。K-M曲线显示恩格列净组12个月时心衰再入院率显著低于对照组(P=0.049)。多因素Cox回归分析显示恩格列净是心衰再入院的独立保护因素。结论:脓毒症合并急性心衰的2型糖尿病患者应用恩格列净可以显著降低患者12个月心衰再入院率。Objective:To explore the effect of empagliflozin on the type 2 diabetes mellitus patients with sepsis and acute heart failure.Methods:The 180 patients with sepsis and acute heart failure were divided into empagliflozin group with 79 cases and control group with 101 cases according to different treatment methods.The incidence of 12-month all-cause death and rehospitalization with heart failure were compared between the two groups.The survival curve was drawn by Kaplan-Meier(K-M)method.The risk factors of readmission were analyzed by Cox regression.Results:There was no significant difference in 12-month all-cause mortality between the two groups.K-M curve showed that the rehospitalization rate of heart failure at 12 months in the empagliflozin group was significantly lower than that in the control group(P=0.049).Multivariate Cox regression analysis showed that empagliflozin was an independent protective factor for rehospitalization of heart failure.Conclusion:Empagliflozin can significantly reduce the rehospitalization rate of heart failure in 12 months in type 2 diabetic patients with sepsis and acute heart failure.

关 键 词：脓毒症 急性心力衰竭 2型糖尿病 恩格列净 

分 类 号：R541.6[医药卫生—心血管疾病]